Huiyu Pharmaceuticals: Injection HY0001a has obtained approval for drug clinical trials.

Huiyu Pharmaceuticals announced that its wholly-owned subsidiary, Huiyu Haiyue, has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial of the bio-innovative drug injection HY0001a for the treatment of advanced solid tumors has been approved. The injection HY0001a is an antibody-drug conjugate developed independently by the company, registered as a Class 1 innovative therapeutic biological product. As of the disclosure date of the announcement, there are no other products targeting the same target approved for marketing domestically or internationally. This product is the world's first drug to be disclosed for clinical trials targeting this target.